A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease

Trial Profile

A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Pain; Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms Hestia2
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 05 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Nov 2016.
    • 05 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top